We are live on ! Find out more
TGTX icon

TG Therapeutics

355 hedge funds and large institutions have $3.58B invested in TG Therapeutics in 2025 Q3 according to their latest regulatory filings, with 49 funds opening new positions, 102 increasing their positions, 136 reducing their positions, and 48 closing their positions.

New
Increased
Maintained
Reduced
Closed

2% more first-time investments, than exits

New positions opened: 49 | Existing positions closed: 48

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

1% less funds holding

Funds holding: 357 → 355 (-2)

2% less call options, than puts

Call options by funds: $80.5M | Put options by funds: $82M

1.62% less ownership

Funds ownership: 64.03% → 62.41% (-1.6%)

23% less capital inflows, than outflows

Capital inflows: $336M | Capital outflows: $434M

25% less repeat investments, than reductions

Existing positions increased: 102 | Existing positions reduced: 136

Holders
355
Holders Change
-2
Holders Change %
-0.56%
% of All Funds
4.63%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
49
Increased
102
Reduced
136
Closed
48
Calls
$80.5​M
Puts
$82​M
Net Calls
-⁠$1.51​M
Net Calls Change
-⁠$30.1​M

TGTX Hedge Fund Activity: Q3 2025 in Review

355 of the 7,660 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q3 2025, worth a combined $3.58B — down 2% from $3.65B a quarter earlier.

Buyers outnumbered sellers: 49 funds opened new TGTX positions and 48 closed out — a net gain of 1 holder — while 102 added to existing stakes and 136 trimmed.

The largest buyer was Soleus Capital Management, adding an estimated $52.7M. The largest seller was Wellington Management Group, cutting an estimated $38.5M.

  • 355 institutional investors held TG Therapeutics (TGTX) as of Q3 2025, down from 357 in Q2 2025.
  • Funds reported $3.58B of TG Therapeutics stock for Q3 2025, down 2% quarter-over-quarter.
  • 49 funds opened new TG Therapeutics positions in Q3 2025 and 48 closed out, a net change of +1 holder.
  • The largest TG Therapeutics buyer in Q3 2025 was Soleus Capital Management, an estimated $52.7M added.
  • The largest TG Therapeutics seller in Q3 2025 was Wellington Management Group, an estimated $38.5M sold.

Based on aggregated 13F filings for Q3 2025.